Compare Invitation Homes Inc. Common Stock (INVH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Pfizer Inc — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.70B), while Pfizer Inc trades at $29.41 (market cap $161.70B). The key difference: Pfizer Inc is far larger — about 10.3× Invitation Homes Inc. Common Stock's market cap, and Pfizer Inc pays the higher dividend (6.06%). Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Pfizer Inc for 158 Days on average.
| INVH | PFE | |
|---|---|---|
Market Cap | $15.70B | $161.70B |
Volume | 4,685,416 | 26,828,084 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $29.21 |
52-Week Low | $24.39 | $23.67 |
Typical Hold Time | 0 Days | 158 Days |
Enterprise Value | $24.16B | $213.20B |
Dividend Yield | 4.51% | 6.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.
Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
